Shoreline Biosciences is developing an off-the-shelf, targeted, allogeneic approach to natural killer (NK) and macrophage cell therapies which the immunotherapy company’s chairman and CEO believes is one-of-a-kind.
In this webinar, a panel of experts will discuss whether autologous therapies here to stay; if allogeneic therapies are the future; and the unlimited scope of gene editing technologies.
Backed by Leaps by Bayer, Bay Area-based Senti Biosciences secured $105 million in a Series B financing round that will help the company advance its therapeutic pipeline of allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapies.
Takeda Pharmaceutical opened a new 24,000-square-foot R&D cell therapy manufacturing facility in Boston at the site of the company’s R&D headquarters.
